Why the study?
Does the fixed combination of Perindopril/Indapamide provide efficacy, safety, and metabolic neutrality in patients with arterial hypertension and obesity, type 2 diabetes, or metabolic syndrome?
Does the fixed combination of Perindopril/Indapamide provide efficacy, safety, and metabolic neutrality in patients with arterial hypertension and obesity, type 2 diabetes, or metabolic syndrome?
Perindopril/Indapamide fixed combination is an effective, safe, and metabolically neutral option for managing hypertension in obese patients.
Should not yet change practice in obese hypertension; leaves open RCTs confirming real-world efficacy and metabolic neutrality of this combination.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Peter Wohlfahrt (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: